Every 10-Q that China Pharma (CPHI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CPHI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CPHI filings page.
China Pharma Holdings, Inc. reported continuing losses and tight liquidity for the six months ended June 30, 2026. Revenue was $1.93 million, down 10.6% from $2.16 million a year earlier, but gross margin improved from a loss to a 19.1% profit margin as certain equipment became fully depreciated and inventory write-downs declined.
The company recorded a net loss of $2.60 million versus $1.31 million in the prior-year period, driven largely by higher amortization on newly acquired pharmaceutical patents. Cash and cash equivalents were only $0.30 million, and current liabilities exceeded current assets by $5.7 million. Management highlights a significant accumulated deficit of $49.8 million and relies on related-party loans, including $1.64 million advanced by the chairperson, to fund operations.
To expand its pipeline, the company issued 25,000,000 shares for intangible assets valued at $14.99 million, and subsequent to quarter-end raised $5.0 million gross (net $4.43 million) by selling 2,500,000 shares at $2.00 per share to an institutional investor. Intangible assets rose to $38.34 million, while Helpson’s operations remain concentrated in China and exposed to pricing pressure from national centralized procurement and evolving consistency-evaluation policies.
China Pharma Holdings reported Q1 2026 revenue of $0.98 million, down from $1.14 million a year earlier, as some key products faced weaker demand and competition from China’s centralized procurement system. The product mix shifted toward cardiovascular and cerebrovascular drugs, which became the largest revenue contributor.
The company posted a net loss of $1.14 million, wider than the $0.79 million loss in Q1 2025, mainly due to sharply higher amortization from recently acquired drug patents. Although gross margin improved to 29.0% from a prior gross loss, operating loss still reached $1.12 million.
Liquidity remains strained. Cash and cash equivalents were $0.17 million at March 31, 2026, and current liabilities exceeded current assets by $5.3 million. The CEO has advanced about $1.47 million in related-party loans, and management disclosed that these conditions create substantial doubt about the company’s ability to continue as a going concern.
During the quarter, China Pharma significantly expanded its intangible asset base by issuing 25,000,000 shares of common stock, valued at $15.0 million, to acquire two invention patents. This lifted total shares outstanding to 40,522,002 and increased stockholders’ equity but also materially diluted existing shareholders.
China Pharma Holdings (CPHI) reported Q3 2025 results showing continued losses amid tight liquidity. Revenue was $756,217, with a gross loss of $59,654 and net loss of $651,482 (loss per share $0.17). For the nine months, revenue was $2,918,271 and net loss was $1,965,421.
The company flagged substantial doubt about its ability to continue as a going concern. Cash and equivalents were $267,625 as of September 30, 2025, and current liabilities exceeded current assets by $4.3 million. Borrowings from the Chair/CEO totaled $1,413,340, supporting working capital.
Results improved year over year on lower depreciation and reduced inventory obsolescence, narrowing gross loss and operating loss. The company wrote off $13.7 million of long‑aged receivables in August 2025, sharply reducing the allowance. It also issued 1,760,000 shares for a patent asset valued at $2.446 million. A 1‑for‑10 reverse split took effect April 15, 2025; shares outstanding were 5,022,002 as of November 10, 2025.